...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New trial

It did lessen the value of RVX by the value of the IP moved to Zenith. At the time, RVX value that at and maybe some cash, royaltiy shares,  etc. at 9.1% of pre-spinout RVX. That is what we paid for the Zenith shares.

Share
New Message
Please login to post a reply